Navigation Links
Access and Somanta Announce Data to be Presented on Angiolix at,ASCO Oncology Conference

Pre-clinical Data Suggests Angiolix Can Inhibit Breast Cancer Growth By 75%

DALLAS and IRVINE, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (Bulletin Board: ACCP) and Somanta Pharmaceuticals, Inc. (Bulletin Board: SMPM) announced today that a scientific abstract outlining new preclinical efficacy data for Somanta's Angiolix has been selected for publication in the Proceedings of the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, IL, June 1-5, 2007. The data, in a study conducted using mouse models, shows that Angiolix has been able to achieve more than 75% growth inhibition of human breast cancer growing as xenografts in mouse.

ASCO's annual meeting is the world's premier oncology conference providing information on the latest developments in cancer treatment. As previously announced Access and Somanta have signed a definitive merger agreement for Access to acquire Somanta as a step in the creation of a combined company with a broad cancer-focused portfolio in which Angiolix will be a major program.

Angiolix is a humanized monoclonal antibody that recognizes a migrating adhesion molecule called Lactadherin. Somanta's recent data suggests that tumor cells express Lactadherin which is a factor in the growth of tumor vasculature. Several existing or potential anti-cancer drugs (such as Avastin) seek to block tumor vascularization by blocking a signaling protein know as vascular endothelial growth factor (VEGF). The binding of Angiolix to Lactadherin is thought to cause a VEGF-independent integrin receptor signaling cascade that blocks vascular endothelial cell proliferation. Due to its ability to neutralize Lactadherin-integrin receptor binding, Angiolix may be able to specifically target breast cancer cells and thereby cause tumor suppression by blocking the growth of tumor vasculature.

Dr. Agamemnon Epenetos, CEO of Som
'"/>




Page: 1 2 3

Related medicine technology :

1. PromegaExpress Expands Easy Access to Products with New Cabinet
2. Access Pharmaceuticals Announces Poster Presentations on ProLindac at the American Association for Cancer Research 2007 Annual Meeting
3. Somanta Announces the Presentation of Alchemix Data at The American Association for Cancer Research Annual Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:5/23/2013)... , May 23, 2013   BioLife Solutions ... of proprietary clinical grade hypothermic storage and ... and contract aseptic media manufacturer , today announced ... & Regenerative Medicine Congress 2013 this week in ... http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO ) Dr. Aby J. Mathew, BioLife,s ...
(Date:5/23/2013)... SAN DIEGO and PARIS ... VOLC ), a leading developer and manufacturer of ... and treatment of coronary and peripheral vascular disease, today ... V asodilator I ndependent S tenosis ... late breaking clinical trial session at EuroPCR 2013. These ...
(Date:5/23/2013)... LAUSANNE , Switzerland ... 23, 2013 Cenix BioScience, ... developer specialized in RNAi-, miRNA- and high content-driven ... biopharmaceutical group of companies with a focus on ... medical needs, including oncology and companion diagnostics, today ...
Breaking Medicine Technology:BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 2Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 3Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 4Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 5Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 2Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 3Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers 4
... IOMI ) today announced that Stanley C. Erck, the ... Acumen BioFin,Rodman & Renshaw 9th Annual Healthcare Conference in ... will begin at 9:10 a.m. Eastern,Time in the Kennedy ... Mr. Erck,s presentation will focus on Iomai,s portfolio of ...
... Exelixis, Inc. (Nasdaq:,EXEL) today presented data from ... with albuminuria due to diabetic nephropathy. XL784 is ... enzymes that may,play a role in the pathogenesis ... presented during a poster session (Abstract/Poster PO1030) at,the ...
Cached Medicine Technology:Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5 2Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 2Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 3Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 4
(Date:5/23/2013)... 23, 2013 Jim Fitzpatrick just did ... Advertising developed yet another outside-of-the-box approach to reaching the ... he brings daily newscasts to the retail automotive industry, ... of a broadcast news format. , CBTNews.com is ... news. Co-anchors Bridget Everett and Russell Brown host the ...
(Date:5/23/2013)... 23, 2013 To better serve ... company, is pleased to announce the release of ... its pacesetting space division products. Provided by Koroseal, ... the new patterns and colors represent a sophisticated ... meetings with a team of Koroseal experts, Modernfold ...
(Date:5/23/2013)... now, little was scientifically known about the human potential ... for people who are suffering in a way that ... researchers at the Center for Investigating Healthy Minds at ... that adults can be trained to be more compassionate. ... Psychological Science , is the first to investigate whether ...
(Date:5/23/2013)... New techniques in imaging of brain activity developed ... Neurological Institute, and his colleagues lead to improved ... combination of electroencephalogram (EEG) and functional magnetic resonance ... the areas generating epileptic seizures, giving neurosurgeons a ... if appropriate. These results were presented at ...
(Date:5/23/2013)... HealthDay Reporter , , WEDNESDAY, May 22 (HealthDay News) -- Physicians ... lung cancer now have more information to help with the ... that low-dose CT scans pick up significantly more lung tumors ... of smoking are at high risk for lung cancer, the ... have to consider the potential harm of radiation exposure when ...
Breaking Medicine News(10 mins):Health News:Fitzpatrick Advertising Founder Brings Auto Industry into Focus with CBT News 2Health News:Modernfold Debuts New Colors and Patterns for Space Division Products 2Health News:Study shows people can be trained to be more compassionate 2Health News:Study shows people can be trained to be more compassionate 3Health News:Study shows people can be trained to be more compassionate 4Health News:New imaging techniques used to help patients suffering from epilepsy 2Health News:CT Scans Reduce Lung Cancer Deaths, Study Confirms 2Health News:CT Scans Reduce Lung Cancer Deaths, Study Confirms 3
... ... ... ... ...
... ... ... ... ...
... ... ... ... ...
... ... ... ... ...
... Two stroke-prevention procedures are safe and equally beneficial for ... effectiveness does vary by age, say researchers at the ... other North American stroke investigators. In findings reported ... Antonio, Texas, the researchers say physicians now have better ...
... on routes they knew well , FRIDAY, Feb. 26 ... drivers can make fatal mistakes on familiar routes, German ... brain activity in 16 experienced and 16 less experienced ... the routes on the simulator, the participants, brains were ...
Cached Medicine News:Health News:Stroke Conference Daily News Summary -- Friday 2Health News:Stroke Conference Daily News Summary -- Friday 3Health News:Stroke Conference Daily News Summary -- Friday 4Health News:Stroke Conference Daily News Summary -- Friday 5Health News:Stroke Conference Daily News Summary -- Friday 6Health News:Aurora BayCare Hosts Statewide Medical Device Business Development Meeting 2Health News:Aurora BayCare Hosts Statewide Medical Device Business Development Meeting 3Health News:Aurora BayCare Hosts Statewide Medical Device Business Development Meeting 4Health News:Aurora BayCare Hosts Statewide Medical Device Business Development Meeting 5Health News:Aurora BayCare Hosts Statewide Medical Device Business Development Meeting 6Health News:Aurora BayCare Hosts Statewide Medical Device Business Development Meeting 7Health News:National Alliance for Hispanic Health Urges Action on Insurance Access as First Step to Achieving Best Health Outcomes for All 2Health News:National Alliance for Hispanic Health Urges Action on Insurance Access as First Step to Achieving Best Health Outcomes for All 3Health News:National Alliance for Hispanic Health Urges Action on Insurance Access as First Step to Achieving Best Health Outcomes for All 4Health News:American National Announces Corrected Dividend Dates 2Health News:Study: Choice between stroke-prevention procedures influenced by patient age 2Health News:Study: Choice between stroke-prevention procedures influenced by patient age 3
...
...
The Lineage acetabular system with metal liners uses sophisticated manufacturing methods and materials to minimize wear debris generation....
The Pivot Bipolar was designed with a simple one-step assembly interface between the femoral head and the compression molded liner which requires no instruments and reduces OR time....
Medicine Products: